Translocating Lactobacillus torments tumors via tryptophan catabolism
- PMID: 37116468
- DOI: 10.1016/j.cell.2023.03.022
Translocating Lactobacillus torments tumors via tryptophan catabolism
Abstract
Variability in the efficacy of immune checkpoint inhibitors in cancer patients is associated with the human gut microbiota. However, detailed mechanisms are unclear. In this issue of Cell, Bender et al. uncovered that a probiotic Lactobacillus strain translocates into murine tumors to enhance immunotherapy via the tryptophan metabolite indole-3-aldehyde (I3A).
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.A.K. received salary, consulting fees, honoraria, or research funds from Eligo Biosciences, Enterome, Roche, Novartis, Bristol–Meyers Squibb, AbbVie, GlaxoSmithKline, MSD Sharpe & Dohme, and Cell Applications, and holds a patent on the use of microbiota manipulations to treat immune-mediated diseases. M.S.P. declares no competing interests.
Comment on
-
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment.Cell. 2023 Apr 27;186(9):1846-1862.e26. doi: 10.1016/j.cell.2023.03.011. Epub 2023 Apr 6. Cell. 2023. PMID: 37028428 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical